Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Head and Neck Cancers
•
Melanoma/Skin Cancer
•
Medical Oncology
Any role for adjuvant systemic therapy for resected sebaceous skin carcinoma?
Related Questions
Is day 43 cisplatin 100mg/m2 needed after completion of RT in case of a delay related to neutropenia for locally advanced head and neck cancer?
What scenario would flipped dosing versus standard dosing of Ipilimumab+Nivolumab be beneficial in metastatic melanoma?
How, if at all, does your approach to adjuvant chemoradiation differ with proton beam radiation vs. conventional photon radiation for H&N Cancers?
Would you offer a 2nd generation anti-AR or abiraterone after progression on ADT in patients with metastatic AR+, HER2 expressing salivary gland carcinoma?
When would you offer nivolumab/relatlimab to a metastatic melanoma patient following progression on BRAF/MEK targeted therapy?
Is the phase 2 data regarding neoadjuvant cemiplimab in cutaneous squamous cell carcinoma sufficient to adopt for all patients or will you await phase 3 data?
What criteria does your institution use to indicate patient is ready for PEG tube removal?
What are your top takeaways in Head & Neck Cancers from ASCO 2022?
Are you routinely using neoadjuvant cemiplimab for cutaneous squamous cell carcinoma of any site?
Would you offer adjuvant therapy for a patient with Stage IIIB melanoma (pT2aN1c) (microsatellite only) following wide excision with negative SLN?
